152 related articles for article (PubMed ID: 1452117)
21. A dynamic test to investigate potential tissue plasminogen activator activity. Comparison of deamino-8-D-argininevasopressin with venous occlusion in normal subjects and patients.
Sultan Y; Harris A; Strauch G; Venot A; De Lauture D
J Lab Clin Med; 1988 Jun; 111(6):645-53. PubMed ID: 3131470
[TBL] [Abstract][Full Text] [Related]
22. Plasminogen activator inhibitor-1 activity in type 2 diabetes: a different relationship with coronary heart disease and diabetic retinopathy.
Brazionis L; Rowley K; Jenkins A; Itsiopoulos C; O'Dea K
Arterioscler Thromb Vasc Biol; 2008 Apr; 28(4):786-91. PubMed ID: 18239151
[TBL] [Abstract][Full Text] [Related]
23. Fibrinolytic activity in Chinese patients with diabetes or hyperlipidemia in comparison with healthy controls.
Ho CH; Jap TS
Thromb Haemost; 1991 Jan; 65(1):3-6. PubMed ID: 1902595
[TBL] [Abstract][Full Text] [Related]
24. Contact system dependent fibrinolytic activity in vivo: observations in healthy subjects and factor XII deficient patients.
Levi M; Hack CE; de Boer JP; Brandjes DP; Büller HR; ten Cate JW
Agents Actions Suppl; 1992; 38 ( Pt 2)():292-8. PubMed ID: 1462834
[TBL] [Abstract][Full Text] [Related]
25. Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity.
Agren A; Wiman B; Schulman S
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):657-60. PubMed ID: 17890953
[TBL] [Abstract][Full Text] [Related]
26. Type 2 diabetes: assessment of endothelial lesion and fibrinolytic system markers.
Soares AL; Sousa Mde O; Dusse LM; Fernandes AP; Lasmar MC; Novelli BA; Lages Gde F; Carvalho Md
Blood Coagul Fibrinolysis; 2007 Jul; 18(5):395-9. PubMed ID: 17581312
[TBL] [Abstract][Full Text] [Related]
27. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
28. Tissue-type plasminogen activator after venous occlusion in pregnancy and puerperium.
Stegnar M; Zore A; Novak-Antolic Z; Vovk N; Kruithof EK
Thromb Haemost; 1993 Sep; 70(3):486-90. PubMed ID: 8259554
[TBL] [Abstract][Full Text] [Related]
29. Sex differences in the determinants of fibrinolytic activity.
MacCallum PK; Cooper JA; Howarth DJ; Meade TW; Miller GJ
Thromb Haemost; 1998 Mar; 79(3):587-90. PubMed ID: 9531046
[TBL] [Abstract][Full Text] [Related]
30. Circulating tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in proliferative diabetic retinopathy: a pilot study.
Simpson AJ; Booth NA; Moore NR; Lewis SJ; Gray RS
Acta Diabetol; 1999 Sep; 36(3):155-8. PubMed ID: 10664320
[TBL] [Abstract][Full Text] [Related]
31. [Changes in microcirculation and selected laboratory parameters in the early stages of diabetic microangiopathy].
Skrha J; Prázný M; Kvasnicka J; Kalvodová B
Cas Lek Cesk; 2001 Jun; 140(12):370-4. PubMed ID: 11503186
[TBL] [Abstract][Full Text] [Related]
32. Fibrinolytic dysfunction in insulin-resistant women with previous gestational diabetes.
Farhan S; Winzer C; Tura A; Quehenberger P; Bieglmaier C; Wagner OF; Huber K; Waldhäusl W; Pacini G; Kautzky-Willer A
Eur J Clin Invest; 2006 May; 36(5):345-52. PubMed ID: 16634839
[TBL] [Abstract][Full Text] [Related]
33. Tissue plasminogen activator and plasminogen activator inhibitor 1 in obese and lean patients with polycystic ovary syndrome.
Lindholm A; Bixo M; Eliasson M; Hudecova M; Arnadottir R; Holte J; Poromaa IS
Gynecol Endocrinol; 2010 Oct; 26(10):743-8. PubMed ID: 20500107
[TBL] [Abstract][Full Text] [Related]
34. Regulation of tissue-type plasminogen activator-mediated fibrinolysis by plasminogen activator inhibitor type-1 in patients with ischaemic heart disease: possible unfavourable effect of diuretics.
Pedersen OD; Gram J; Bagger H; Keller N; Jespersen J
Coron Artery Dis; 1994 Jul; 5(7):617-23. PubMed ID: 7952424
[TBL] [Abstract][Full Text] [Related]
35. Coagulation profile in diabetes and its association with diabetic microvascular complications.
Madan R; Gupt B; Saluja S; Kansra UC; Tripathi BK; Guliani BP
J Assoc Physicians India; 2010 Aug; 58():481-4. PubMed ID: 21189694
[TBL] [Abstract][Full Text] [Related]
36. Fibrinolytic responses to 1-desamino-8-D-arginine-vasopressin in patients with congenital nephrogenic diabetes insipidus.
Knoers N; Brommer EJ; Willems H; van Oost BA; Monnens LA
Nephron; 1990; 54(4):322-6. PubMed ID: 2109264
[TBL] [Abstract][Full Text] [Related]
37. Fibrinolytic system in adolescents: response to venous occlusion stress tests.
Monagle P; Chan AK; Albisetti M; Vegh P; Andrew M; Mitchell L
Pediatr Res; 2003 Feb; 53(2):333-7. PubMed ID: 12538795
[TBL] [Abstract][Full Text] [Related]
38. Fibrinogen, fibrinolysis and diabetes mellitus: a comment.
Vague P; Juhan-Vague I
Diabetologia; 1997 Jun; 40(6):738-40. PubMed ID: 9222657
[No Abstract] [Full Text] [Related]
39. Contrasting fibrinolytic responses in type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes.
Walmsley D; Hampton KK; Grant PJ
Diabet Med; 1991 Dec; 8(10):954-9. PubMed ID: 1838048
[TBL] [Abstract][Full Text] [Related]
40. Markers of fibrinolysis may predict development of lower extremity arterial disease in patients with diabetes: A longitudinal prospective cohort study with 10 years of follow-up.
Rautio A; Boman K; Eriksson JW; Svensson MK
Diab Vasc Dis Res; 2016 May; 13(3):183-91. PubMed ID: 26818227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
